Objectives Two phase III trials of advanced NSCLC patients were compared to examine
relative efficacy and safety of differing treatment regimens. The JMDB trial investigated first …

Background In a phase III study, maintenance pemetrexed showed superior survival over
placebo (PARAMOUNT) for patients with advanced non-squamous non-small cell lung …

Purpose In the phase III PARAMOUNT trial, pemetrexed continuation maintenance therapy
reduced the risk of disease progression versus placebo (hazard ratio [HR], 0.62; 95% CI …

Introduction: The PARAMOUNT phase III trial demonstrated that pemetrexed continuation
maintenance significantly reduced the risk of disease progression (hazard ratio= 0.62) and …

Abstract Introduction In the PARAMOUNT (“A Phase 3, Double-Blind, Placebo-Controlled
Study of Maintenance Pemetrexed plus Best Supportive Care vs. Best Supportive Care …

Introduction This study prospectively evaluated the efficacy and safety of pemetrexed and
carboplatin followed by maintenance pemetrexed in chemo-naïve patients with advanced …

INTRODUCTION: The primary objectives of this study were to determine the recommended
dose of pemetrexed and carboplatin in patients with chemo-naive advanced non-small cell …

Abstract Learning Objectives After completing this course, the reader will be able to:
Consider tumor histology when making treatment decisions for patients with NSCLC. Identify …

Background Subgroup analyses of randomized studies have consistently shown that
pemetrexed is exclusively effective in non-small-cell lung cancer (NSCLC) other than …

Aim: We conducted a phase II study to evaluate the efficacy and safety of pemetrexed
continuation-maintenance after carboplatin-based induction for advanced non-squamous …